196 related articles for article (PubMed ID: 2871948)
1. Does growth hormone releasing factor desensitize the somatotroph? Interpretation of responses of growth hormone during and after 10-hour infusion of GRF 1-29 amide in man.
Davis JR; Sheppard MC; Shakespear RA; Lynch SS; Clayton RN
Clin Endocrinol (Oxf); 1986 Feb; 24(2):135-40. PubMed ID: 2871948
[TBL] [Abstract][Full Text] [Related]
2. Human pancreatic growth hormone releasing factor (hpGRF): GRF- and GH-levels after bolus injection and infusion of hpGRF.
von Werder K; Losa M; Stalla GK; Bock L; Müller OA
Acta Neurochir (Wien); 1985; 75(1-4):81-7. PubMed ID: 2986424
[TBL] [Abstract][Full Text] [Related]
3. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.
Vance ML; Kaiser DL; Evans WS; Furlanetto R; Vale W; Rivier J; Thorner MO
J Clin Invest; 1985 May; 75(5):1584-90. PubMed ID: 2860126
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone releasing factor infusion does not sustain elevated GH-levels in normal subjects.
Losa M; Bock L; Schopohl J; Stalla GK; Müller OA; von Werder K
Acta Endocrinol (Copenh); 1984 Dec; 107(4):462-70. PubMed ID: 6440392
[TBL] [Abstract][Full Text] [Related]
5. Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation.
Webb CB; Vance ML; Thorner MO; Perisutti G; Thominet J; Rivier J; Vale W; Frohman LA
J Clin Invest; 1984 Jul; 74(1):96-103. PubMed ID: 6429198
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone response to low dose intravenous injections of growth hormone releasing factor in obese and normal weight women.
Kopelman PG; Noonan K
Clin Endocrinol (Oxf); 1986 Feb; 24(2):157-64. PubMed ID: 2871950
[TBL] [Abstract][Full Text] [Related]
7. Clonidine pretreatment modifies the growth hormone secretory pattern induced by short-term continuous GRF infusion in normal man.
Lima L; Arce V; Diaz MJ; Tresguerres JA; Devesa J
Clin Endocrinol (Oxf); 1991 Aug; 35(2):129-35. PubMed ID: 1934527
[TBL] [Abstract][Full Text] [Related]
8. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
[TBL] [Abstract][Full Text] [Related]
9. Effect of thyrotropin-releasing hormone on growth hormone release in normal subjects pretreated with human pancreatic growth hormone-releasing factor 1-44 pulsatile administration.
Sartorio A; Spada A; Bochicchio D; Atterrato A; Morabito F; Faglia G
Neuroendocrinology; 1986; 44(4):470-4. PubMed ID: 3102991
[TBL] [Abstract][Full Text] [Related]
10. Pituitary growth hormone response in rats during a 24-hour infusion of growth hormone-releasing factor.
Wehrenberg WB; Brazeau P; Ling N; Textor G; Guillemin R
Endocrinology; 1984 May; 114(5):1613-6. PubMed ID: 6143658
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone (GH) secretion in the dwarf rat: release, clearance and responsiveness to GH-releasing factor and somatostatin.
Carmignac DF; Robinson IC
J Endocrinol; 1990 Oct; 127(1):69-75. PubMed ID: 1983310
[TBL] [Abstract][Full Text] [Related]
12. Plasma growth hormone (GH) response to intravenous GH-releasing factor (GRF) in adult rats: evidence for transient pituitary desensitization after GRF stimulation.
Arsenijevic Y; Rivest RW; Eshkol A; Sizonenko PC; Aubert ML
Endocrinology; 1987 Oct; 121(4):1487-96. PubMed ID: 2888646
[TBL] [Abstract][Full Text] [Related]
13. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
Massoud AF; Hindmarsh PC; Brook CG
Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone responses to growth hormone-releasing factor (1-29) in euthyroid, hypothyroid and hyperthyroid rats.
Dieguez C; Jordan V; Harris P; Foord S; Rodriguez-Arnao MD; Gomez-Pan A; Hall R; Scanlon MF
J Endocrinol; 1986 Apr; 109(1):53-6. PubMed ID: 2871123
[TBL] [Abstract][Full Text] [Related]
15. Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29.
Jordan V; Dieguez C; Lafaffian I; Rodriguez-Arnao MD; Gomez-Pan A; Hall R; Scanlon MF
Clin Endocrinol (Oxf); 1986 Mar; 24(3):291-8. PubMed ID: 2871952
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children.
Dickerman Z; Guyda H; Tannenbaum GS
J Clin Endocrinol Metab; 1993 Sep; 77(3):652-7. PubMed ID: 8257527
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone responses to multiple injections of a fragment of human growth hormone-releasing factor in conscious male and female rats.
Clark RG; Robinson IC
J Endocrinol; 1985 Sep; 106(3):281-9. PubMed ID: 2864380
[TBL] [Abstract][Full Text] [Related]
18. Blockade of growth hormone-releasing factor (GRF) activity in the pituitary and hypothalamus of the conscious rat with a peptidic GRF antagonist.
Lumpkin MD; McDonald JK
Endocrinology; 1989 Mar; 124(3):1522-31. PubMed ID: 2537185
[TBL] [Abstract][Full Text] [Related]
19. Differential responsiveness of the somatotroph to growth hormone-releasing factor during early neonatal development in the rat.
Szabo M; Cuttler L
Endocrinology; 1986 Jan; 118(1):69-73. PubMed ID: 3000750
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous treatment with growth hormone-releasing hormone for short stature.
Hernández M; Fragoso J; Barrio R; Argente J; Arilla E
Horm Res; 1988; 30(6):252-7. PubMed ID: 2907992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
